BILLERICA, Mass. – Aug. 27, 2021 – (BUSINESS WIRE) – Quanterix Corporation (NASDAQ: QTRX),
a company digitizing biomarker analysis to advance the science of precision health, today
released the following statement in response to news reports related to Cassava Sciences.
Cassava previously engaged Quanterix’ Accelerator laboratory to perform sample testing based
on blinded samples provided by Cassava. Quanterix or its employees did not interpret the test
results or prepare the data charts presented by Cassava at the Alzheimer’s Association
International Conference (AAIC) in July 2021 or otherwise.
Quanterix is widely recognized for its commitment to business integrity and to upholding the
highest standards of quality. Quanterix’ Simoa technology provides exquisite sensitivity for
detecting and measuring biomarkers across a wide range of disease states, including neurology,
oncology, and infectious disease. The Simoa technology has been trusted by 24 of the top 25
top pharmaceutical companies, and Quanterix customers have described the use of Simoa
technology in over 1,300 research papers and presentations worldwide.
Quanterix harnesses the power of biomarkers with the latest detection solutions to enable a
precision health vision of proactive, preventative healthcare and believes that, in doing so, can
change the course of how diseases like Alzheimer’s are currently studied and treated.
Please direct inquiries to: quanterix@pancomm.com.
Related Posts
Quanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026
Molecular Barcoding Kit Now Available Globally; TIME and high-plex ADC panels confirmed for Q4 shipment; Accelerator Laboratory Services open custom ADC panel development BILLERICA, Mass.–September 25, 2026–Quanterix Corporation (NASDAQ: QTRX)…
Quanterix Names Dr. Yuri Fesko Chief Medical Officer
BILLERICA, Mass.–September 14, 2026–Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that accomplished physician executive Dr. Yuri Fesko has been appointed Chief Medical Officer of…
Quanterix Releases Financial Results for the Second Quarter of 2026
Reports $32.9 million in revenue and $96.9 million of cash and marketable securities Company accelerating initiatives to drive commercial effectiveness Revises financial outlook for 2026 and extends date for attaining…
Quanterix Names Jim Gute Chief Commercial Officer
Brings 20 years of senior commercial leadership in healthcare and IT, including GE Healthcare and Exact Sciences BILLERICA, Mass.–August 10, 2026–Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker…
Quanterix To Participate in Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12
BILLERICA, Mass. – August 6, 2026 – Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that senior management will participate in the Canaccord Genuity Capital…
Quanterix To Report Second Quarter 2026 Financial Results on August 10, 2026
BILLERICA, Mass. – August 4 2026 – Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that it will host a conference call on Monday, August…
Anthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD® Complete; Quanterix to Present New Data Highlighting Multi-Analyte Advantages
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BILLERICA, Mass. – June 16, 2026 – Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on June 15,…